Fed Governor Cook sues Trump over firing attempt
Peggie Pelosi, a director at USANA Health Sciences Inc . (NYSE:USNA), recently sold a portion of her holdings in the company amid the stock’s 38% decline over the past year. According to a Form 4 filing with the Securities and Exchange Commission, Pelosi sold 780 shares of USANA common stock on February 27, 2025. The shares were sold at $28.10 each, totaling $21,918. InvestingPro analysis indicates the stock is currently trading below its Fair Value, with a P/E ratio of 13.5x.
Following the sale, Pelosi retains ownership of 3,395 shares in the company. The transaction was conducted directly, without equity swaps. Pelosi’s position as a director remains unchanged, with no indications of additional transactions. The company maintains strong financial health with a current ratio of 2.0 and holds more cash than debt on its balance sheet. For deeper insights into insider trading patterns and comprehensive financial analysis, including 10+ additional ProTips, visit InvestingPro.
In other recent news, USANA Health Sciences reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $0.64, compared to the forecasted $0.49. The company also exceeded revenue projections, reporting $214 million against the anticipated $208.84 million. Despite these positive results, USANA’s full-year 2025 earnings guidance fell short of expectations, with a projected EPS range of $2.35-$3.00, below the consensus estimate of $2.87. The company also forecasted revenue between $920-1000 million for FY2025, bracketing the consensus estimate of $934.5 million.
USANA’s recent acquisition of Hiya Health, which contributed minimally to the fourth-quarter results, is expected to boost the company’s presence in the children’s health market. The acquisition is projected to contribute $145-$160 million to net sales in 2025. Analysts noted that USANA’s growth strategy includes launching over 20 new products in 2025 and implementing a new associate incentive program to enhance its direct selling model. Additionally, the company ended the year with $182 million in cash reserves, with plans to increase this by $50-$60 million in 2025.
Despite the positive earnings surprise, the company’s stock experienced a significant drop, reflecting investor concerns about USANA’s ability to meet its growth targets amid challenging market conditions. The company acknowledged difficulties in key markets, particularly in the Asia Pacific region, but remains optimistic about its long-term growth strategy. Analysts from firms like Sidoti and Company and D.A. Davidson have shown interest in the company’s promotional strategies and the integration of Hiya Health, highlighting the operational risks and market challenges USANA faces.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.